Xiuqi Wang

Research Fellow

University of Arkansas for Medical Sciences

postdoc

5 h-index 11 pubs 129 cited

Research Areas

Cancer Treatment and Pharmacology Drug-Induced Hepatotoxicity and Protection Cancer-related molecular mechanisms research Bone health and treatments Kinase Inhibitor Development Drug Transport and Resistance Mechanisms Acute Myeloid Leukemia Research

Links

ORCID Research Group

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

Xiuqi Wang's research focuses on the discovery and development of novel small molecule inhibitors targeting various kinases implicated in cancer. Wang has investigated imidazo[1,2-a]pyridine and pyrimidine derivatives as inhibitors of FLT3 and RET kinases, including those with resistance mutations relevant to acute myeloid leukemia. Recent work has also explored selective inhibitors for aurora kinase B and Pyk2, with a bone-targeting approach for preventing glucocorticoid-induced bone loss. This research involves structure-based optimization and aims to overcome challenges such as secondary mutations in kinase inhibitors and achieve oral activity. Wang has published 11 papers with 129 citations and an h-index of 5. Collaborations include Yuet-Kin Leung, Brendan Frett, Phuc Tran, and Anupreet Kharbanda at the University of Arkansas for Medical Sciences.

Metrics

h-index: 5
Publications: 11
Citations: 129

Selected Publications

Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor (2025) DOI
Generation of BT-Amide, a Bone-Targeted Pyk2 Inhibitor, Effective <i>via</i> Oral Administration, for the Prevention of Glucocorticoid-Induced Bone Loss (2024) DOI
Overcoming Secondary Mutations of Type II Kinase Inhibitors (2024) DOI
An imidazo[1,2-a]pyridine-pyridine derivative potently inhibits FLT3-ITD and FLT3-ITD secondary mutants, including gilteritinib-resistant FLT3-ITD/F691L (2023) DOI
N-(3-Methoxyphenyl)-6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)pyridin-2-amine is an inhibitor of the FLT3-ITD and BCR-ABL pathways, and potently inhibits FLT3-ITD/D835Y and FLT3-ITD/F691L secondary mutants (2023) DOI
Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose (2022) DOI
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor (2021) DOI